Marksans Pharma Limited announced its strongest-ever quarterly performance for the second quarter of FY27, showcasing explosive growth driven by robust international expansions. The pharmaceutical exporter delivered a stellar 44.8% year-on-year (YoY) increase in consolidated net profit, reaching Rs. 143.5 crore compared to ₹99.1 crore in the same period last fiscal year.

For the first time in the company's history, quarterly operating revenue breached the Rs. 900 crore threshold, scaling to Rs. 940.2 crore, up 30.5% YoY from Rs. 720.4 crore. Even when adjusted for recent acquisitions, the company logged a healthy organic growth rate of 25%, highlighting structural strength in its core overseas delivery channels.

The operational efficiency of Marksans Pharma saw massive acceleration, with EBITDA soaring 48.3% YoY to a record Rs. 214.3 crore. Fueled by structural cost alignments, the operating EBITDA margin expanded significantly by 274 basis points to hit 22.8%. For the first half of the fiscal year (H1 FY27), the company's cumulative net profit nearly doubled, jumping 92.5% to Rs. 302.9 crore, which already represents over 70% of its entire full-year profit for FY26.